• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Imaging and Intervention

Screening mammography may not decrease overall mortality in women ages 40-59

byDavid WangandAndrew Bishara
February 14, 2014
in Imaging and Intervention, Obstetrics, Oncology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. A 5 year mammography screening program did not result in a difference in mortality compared to breast examination alone/usual care in women 40-59.

2. 22% of all mammography-detected invasive cancers were considered to be over-diagnoses.

Evidence Rating Level: 2 (Good)

Study Rundown: The use of mammography is a mainstay in breast cancer screening in women >50 years old. However, the exact magnitude of the benefit provided by breast cancer screening has been controversial. The authors of this article presented the results of a 25-year follow-up of a large randomized control trial, which compared 5-year mammography screening to control (breast examination/usual care). Women enrolled were ages 40-59, had no mammograms in the 12 months leading up to the study, had no history of breast cancer, and were not pregnant. In a cohort of over 89,000 participants, the trial demonstrated no difference in 25-year breast cancer specific or all-cause mortality between the mammography and control group. Given this result, the excess number of breast cancer diagnosis made by mammography was considered over-diagnosis of clinically insignificant pathology. Overall, 22% of all screen detected invasive cancers were categorized as over-diagnoses. The results of this study suggests a decreased value of annual mammography screening for women age 50-59 and may lead to diagnosis of cancer which may not be clinically relevant. The strength of this paper is in its high patient compliance as well as the long-term follow-up; however, there are some methodological short-comings that may affect the validity of the trial. In the mammography arm, only 32% of all breast cancer detected was via mammography only. Furthermore, the analysis is based on data from the Canadian National Breast Screening Study, which has been cited by some researchers as flawed for using poor quality mammography machines. In addition, all women received a clinical breast exam before randomization, which may have contaminated the groups so that patients with larger, more palpable tumors were assigned to mammography.

Click to read the study in BMJ

RELATED REPORTS

Pfizer’s Talzenna combo significantly delays prostate cancer progression

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Dipeptidyl peptidase-4 inhibitors may be associated with an increased incidence of malignancy

Click to read an accompanying editorial in BMJ

Relevant Reading: Overdiagnosis in screening mammography in Denmark: population based cohort study

In-Depth [randomized-controlled trial]: This study analyzed results from the Canadian National Breast Screening Study. 89,835 women were followed for incident breast cancer and survival for up to 25 years (mean time of follow-up: 21.9 years). Using a Cox proportional hazards model, there was no statistically significant difference found in the 25 year cumulative mortality from all causes between the mammography and control groups (1.02 95% CI: 0.98-1.06; p=0.28). There was also no statistically significant difference found in breast cancer specific mortality between the two groups (0.99, 95%CI: 0.88-1.12; p=0.87). There was a statistically significant difference in 25 year survival between mammography and control groups, although this was attributed to lead-time and length-time bias. At the end of the 5 year screening, 484 cases of invasive cancer were diagnosed by mammography alone. At 15 years follow-up, there was an excess of 106 diagnoses cases between the mammography and control group. Given similar survival, the authors translated the excess cases to a 22% (106/484) rate of over-diagnosis.

More from this author: First report of acute MERS-CoV infection associated with adverse pregnancy outcome, “Hospital Report Cards” not associated with improved trauma mortality outcomes, Preoperative vitamin D levels may influence post-surgical infection rate, HIV-infected infant potentially cured with antiretroviral therapy, Pediatric appendicitis outcomes in Canada not superior to US

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: Breast Cancercancer screeninghealth policymortalityoncologyover-diagnosispublic healthuspstfwomen ages 40-59
Previous Post

Travel distance to health care associated with advanced colon cancer stage at diagnosis

Next Post

Complement mutation linked to poor response to eculizumab

RelatedReports

Radiation plus hormone therapy may improve prostate cancer survival
Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 1, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Intrapartum serum prolactin may predict risk of postpartum diabetes
Chronic Disease

Dipeptidyl peptidase-4 inhibitors may be associated with an increased incidence of malignancy

March 26, 2026
High frequency of germline mutations observed in triple negative breast cancers
The Scan by 2 Minute Medicine®

Susie Wiles’ breast cancer diagnosis drives national screening surge

March 25, 2026
Next Post
Complement mutation linked to poor response to eculizumab

Complement mutation linked to poor response to eculizumab

Initial trial of conservative management of splenic injury [Pediatrics Classics Series]

Estimated 1 in 14 women worldwide survivors of sexual violence in lifetime

Estimated 1 in 14 women worldwide survivors of sexual violence in lifetime

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Zorevunersen appears safe and may alleviate symptoms in children with Dravet syndrome
  • Apixaban outperforms rivaroxaban in venous thromboembolism bleeding risk
  • Placental abruption during pregnancy is not associated with increased risk of cardiovascular mortality in children
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

The Classics in Medicine Paperback Released!

Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.

amazon-logo_blackGet-it-on-iBooks-badge

Click anywhere to close this announcement

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.